Ovarian cancer

Indication for Doxorubicin

Population group: Suitable for women, only adults (18 years old or older)

Doxorubicin is indicated for treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.

For this indication, competent medicine agencies globally authorize below treatments:

50 mg/m² once every 4 weeks

Route of admnistration


Defined daily dose

50 - 50 mg per m² of body surface area (BSA)

Dosage regimen

From 50 To 50 mg per m² of body surface area (BSA) once every 28 day(s)

Detailed description

Doxorubicin is administered intravenously at a dose of 50 mg/m² once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.

Dosage considerations

To minimise the risk of infusion reactions, the initial dose is administered at a rate no greater than 1 mg/minute. If no infusion reaction is observed, subsequent doxorubicin infusions may be administered over a 60-minute period.

Active ingredient

Doxorubicin is a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects.

Read more about Doxorubicin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner